113 related articles for article (PubMed ID: 33233668)
1. Detection of
Michaelidou K; Koutoulaki C; Mavridis K; Vorrias E; Papadaki MA; Koutsopoulos AV; Mavroudis D; Agelaki S
Cells; 2020 Nov; 9(11):. PubMed ID: 33233668
[No Abstract] [Full Text] [Related]
2. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
[TBL] [Abstract][Full Text] [Related]
4. Detection of KRAS mutations in liquid biopsies from metastatic colorectal cancer patients using droplet digital PCR, Idylla, and next generation sequencing.
Holm M; Andersson E; Osterlund E; Ovissi A; Soveri LM; Anttonen AK; Kytölä S; Aittomäki K; Osterlund P; Ristimäki A
PLoS One; 2020; 15(11):e0239819. PubMed ID: 33237900
[TBL] [Abstract][Full Text] [Related]
5. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of
Fujii T; Barzi A; Sartore-Bianchi A; Cassingena A; Siravegna G; Karp DD; Piha-Paul SA; Subbiah V; Tsimberidou AM; Huang HJ; Veronese S; Di Nicolantonio F; Pingle S; Vibat CRT; Hancock S; Berz D; Melnikova VO; Erlander MG; Luthra R; Kopetz ES; Meric-Bernstam F; Siena S; Lenz HJ; Bardelli A; Janku F
Clin Cancer Res; 2017 Jul; 23(14):3657-3666. PubMed ID: 28096270
[No Abstract] [Full Text] [Related]
6. Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach.
Pender A; Garcia-Murillas I; Rana S; Cutts RJ; Kelly G; Fenwick K; Kozarewa I; Gonzalez de Castro D; Bhosle J; O'Brien M; Turner NC; Popat S; Downward J
PLoS One; 2015; 10(9):e0139074. PubMed ID: 26413866
[TBL] [Abstract][Full Text] [Related]
7. Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients.
Paweletz CP; Heavey GA; Kuang Y; Durlacher E; Kheoh T; Chao RC; Spira AI; Leventakos K; Johnson ML; Ou SI; Riely GJ; Anderes K; Yang W; Christensen JG; Jänne PA
Clin Cancer Res; 2023 Aug; 29(16):3074-3080. PubMed ID: 37279096
[TBL] [Abstract][Full Text] [Related]
8. Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.
Leick KM; Tomanek-Chalkley A; Coleman KL; Chan CHF
Ann Surg Oncol; 2023 Oct; 30(11):6652-6660. PubMed ID: 37303025
[TBL] [Abstract][Full Text] [Related]
9. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.
Motobayashi H; Kitahata Y; Okada KI; Miyazawa M; Ueno M; Hayami S; Miyamoto A; Shimizu A; Sato M; Yoshimura T; Nakamura Y; Takemoto N; Nakai T; Hyo T; Matsumoto K; Yamaue H; Kawai M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):35. PubMed ID: 38277079
[TBL] [Abstract][Full Text] [Related]
10. RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients.
Li Q; Huang HJ; Ma J; Wang Y; Cao Z; Karlin-Neumann G; Janku F; Liu Z
J Cancer; 2020; 11(12):3543-3550. PubMed ID: 32284750
[No Abstract] [Full Text] [Related]
11. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer.
Sellahewa R; Moghaddam SM; Lundy J; Jenkins BJ; Croagh D
Pancreas; 2023 Mar; 52(3):e188-e195. PubMed ID: 37751379
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
Evrard C; Ingrand P; Rochelle T; Martel M; Tachon G; Flores N; Randrian V; Ferru A; Haineaux PA; Goujon JM; Karayan-Tapon L; Tougeron D
Dig Liver Dis; 2023 Nov; 55(11):1562-1572. PubMed ID: 37308396
[TBL] [Abstract][Full Text] [Related]
13. Early detection of pre-malignant lesions in a KRAS
Rakhit CP; Trigg RM; Le Quesne J; Kelly M; Shaw JA; Pritchard C; Martins LM
Dis Model Mech; 2019 Feb; 12(2):. PubMed ID: 30760495
[TBL] [Abstract][Full Text] [Related]
14. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
[TBL] [Abstract][Full Text] [Related]
15. Monitoring mutant KRAS in plasma cell-free DNA can predict disease progression in a patient with multiple myeloma: A case report.
Yamamoto M; Shindo M; Funayama T; Sumi C; Saito T; Toki Y; Hatayama M; Ono Y; Sato K; Mizukami Y; Okumura T
Clin Chim Acta; 2023 Nov; 551():117590. PubMed ID: 37837907
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer.
Hagey DW; Kordes M; Görgens A; Mowoe MO; Nordin JZ; Moro CF; Löhr JM; El Andaloussi S
J Extracell Vesicles; 2021 Oct; 10(12):e12142. PubMed ID: 34595842
[TBL] [Abstract][Full Text] [Related]
17. CRISPR prime editing for unconstrained correction of oncogenic KRAS variants.
Jang G; Kweon J; Kim Y
Commun Biol; 2023 Jun; 6(1):681. PubMed ID: 37391511
[TBL] [Abstract][Full Text] [Related]
18. A Facile Method to Append a Bio-ID Tag to Endogenous Mutant Kras Alleles.
Budagyan K; Cannon AC; Chernoff J
Methods Mol Biol; 2024; 2797():351-362. PubMed ID: 38570472
[TBL] [Abstract][Full Text] [Related]
19. Quantitative detections of TP53 gene mutations improve the diagnosis and prognostic prediction of biliary tract cancers using droplet digital PCR.
Xiao X; Zhou J; Fang M; Ji J; Huang C; Du F; Ai W; Wang Y; Gao Z; Qiu Z; Gao C
J Clin Lab Anal; 2022 Jan; 36(1):e24103. PubMed ID: 34813121
[TBL] [Abstract][Full Text] [Related]
20. Integrating image and gene-data with a semi-supervised attention model for prediction of KRAS gene mutation status in non-small cell lung cancer.
Xue Y; Zhang D; Jia L; Yang W; Zhao J; Qiang Y; Wang L; Qiao Y; Yue H
PLoS One; 2024; 19(3):e0297331. PubMed ID: 38466735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
